期刊文献+

西地那非联合贝前列素钠对大鼠肺动脉高压影响的实验研究 被引量:4

Impact of sildenafil united beraprost sodium on pulmonary hypertension in rats
下载PDF
导出
摘要 目的探讨西地那非联合贝前列素钠对大鼠肺动脉高压的影响是否优于单一用药。方法 60只健康Wistar大鼠随机分为5组,每组12只,分别为空白对照组(CG),实验对照组(PAH)、西地那非组(SIL)、贝前列素钠组(BER)、联合治疗组(COM)。PAH组,SIL组,BER组、COM组大鼠在实验第一天应用野百合碱60 mg/kg一次性腹腔注射,3周后建立大鼠肺动脉高压模型,CG组腹腔注射生理盐水。SIL组大鼠每日应用西地那非灌胃2次,每次30 mg/kg;BER组大鼠每日应用贝前列素钠灌胃2次,每次40μg/kg;COM组大鼠每日应用西地那非(每次30 mg/kg)+贝前列素钠(每次40μg/kg)灌胃2次;CG组与PAH组大鼠正常喂养。持续4周。4周后镜下观察各组间肺血管的形态,右心导管测量肺动脉压力。结果 SIL组肺动脉压力(pulmonary arterial pressure,PAP)为33.4±8.2,BER组PAP为29.4±7.5,COM组MPAP为24.0±7.3。各组间差异均具有统计学意义(P<0.05)。结论西地那非、贝前列素钠都能有效改善大鼠肺动脉压力,两者联合应用其效果明显优于单一用药。 Objective To explore whether combined application of sildenafil and beraprost is more effective than single treatment on rat pulmonary hypertension. Methods Sixty Wistar rats were randomly divided into 5 groups: the normal group (CG), the control group (PAH), sildenafil group (SIL), beraprost group (BER), and sildenafil beraprost combination group (COM). Monocrotaline (60 mg/kg) intraperitoneal injection was used to construct pulmonary hypertension model. The CG group was treated with normal saline. The SIL group was treated with sildenafil 30 mg/kg twice every day. BER group was treated with beraprost twice 40 μg/kg every day. And COM group was treated with sildenafil 30 mg/kg beraprost twice 40 μg/kg every day. Four weeks later, rats were executed for examination. Results Both the SIL group (33.4 ±8.2 ) and BER group (29.4± 7.5 ) showed a lower pulmonary arterial pressure (PAP) compared with the PAH group(41.4 ±8.8). The PAP in the COM group (24.0±7. 3 ) was lower than that in both SIL and BER group (P 〈 O. 05 ). Conclusion Combined application of sildenafil and beraprost is more effective than single treatment on rat pulmonary hypertension.
出处 《哈尔滨医科大学学报》 CAS 北大核心 2013年第5期406-409,共4页 Journal of Harbin Medical University
基金 黑龙江省教育厅科学技术研究项目(11551249)
关键词 西地那非 贝前列素钠 肺动脉高压 sildenafil beraprost sodium pulmonary hypertension
  • 相关文献

参考文献6

二级参考文献62

  • 1Barst RJ,Langleben D,Badesch D,菅鑫妍.使用选择性内皮素A受体拮抗剂sitaxsentan治疗肺动脉高压[J].中国处方药,2006,5(8):29-29. 被引量:38
  • 2冯娟,王玉林.儿童肺动脉高压遗传学及细胞分子学研究进展[J].实用儿科临床杂志,2006,21(22):1580-1582. 被引量:3
  • 3Zaiman A,Fijalkowska L,Hassoun PM,et al.One hundred years of research in the pathogenesis of pulmonary hypertension[J].Am J Respir Cell Mol Biol,2005,33(5):425-431.
  • 4Simonneau G,Galie N,Rubin LJ,et al.Clinical classification of pulmonary hypertension[J].Am Coll Cardiol,2004,43:5s-12s.
  • 5Firth AL,Yuill KH,Smirnov SV.Mitochondria-dependent regulation of Kv currents in rat pulmonary artery smooth muscle cells[J].Am J Physiol Lung Cell Mol Physiol,2008,295 (1):L61-70.
  • 6Bonnet S,Rochefort G,Sutendra G,et al.The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted[J].Proc Natl Acad Sci U S A,2007,104(27):11418-11423.
  • 7De Frutos S,Duling L,Alo D,et al.NFATc3 is required for intermittent hypoxia-induced hypertension[J].Am J Physiol Heart Circ Physiol,2008,294(5):H2382-2390.
  • 8Zhao YD,Courtman DW,Deng Y,et al.Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelia-like progenitor cells:efficacy of combined cell and eNOS gene therapy in established disease[J].Circ Res,2005,96:442-450.
  • 9Asosingh K,Aldred MA,Vasanji A,et al.Circulating angiogenic precursors in idiopathic pulmonary arterial hypertension[J].Am J Pathol,2008,172(3):615-627.
  • 10Chan SY,Loscalzo J.Pathogenicmechanisms of pulmonary arterial hypertension[J].J Mol Cell Cardiol,2008,44(1):14-30.

共引文献134

同被引文献34

引证文献4

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部